ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, miR-138 expression is increased by GATA1, and repressed by BCR/ABL in addition to imatinib resistance in CML.Turrini et al. suggested that miRNA may play a role in imatinib distribution in CML therapy and they found that miR-212 increases the ABCG2 expression upon treatment with imatinib in CML [78].